3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Completed
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Conditions
Prostatic Neoplasms
8
Polycystic Ovary Syndrome
7
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Lung Neoplasms
4
Metabolic Syndrome
3
Insulin Resistance
3
Adenocarcinoma of Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Glioblastoma
2
Carcinoma, Renal Cell
2
pCR Rate
1
Weight Gain
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Motor Activity
1
Melanoma
1
Lymphoma
1
Leukoplakia
1
Leukemia, Myelomonocytic, Acute
1
Interventions
Rituximab
67
Cyclophosphamide
41
fludarabine phosphate
17
Etoposide
17
Doxorubicin
17
Vincristine
16
Prednisone
16
Filgrastim
14
Mycophenolic Acid
13
Cyclosporine
13
Lenalidomide
12
Antilymphocyte Serum
12
Gemcitabine
11
Radiotherapy
10
fludarabine
9
Peripheral Blood Stem Cell Transplantation
9
Methotrexate
9
Whole-Body Irradiation
8
Tacrolimus
8
Melphalan
8
Carboplatin
8
Bortezomib
8
venetoclax
7
Dexamethasone
7
Cord Blood Stem Cell Transplantation
7
Busulfan
7
ibritumomab tiuxetan
6
Ifosfamide
6
Flow Cytometry
6
obinutuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Large B-Cell, Diffuse
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts
NCT02815397
2017-11-17
DLBCL
Rush University Medical Center
Phase 2
Terminated
2 enrolled
3 charts